Denise Hachul

Prof. Dr. Denise Hachul


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Heart Rhythm
Verified
Journal Article
Closed access
RSRobert Sheldon
Robert Sheldon
BGBlair P. Grubb
Blair P. Grubb
BOBrian Olshansky
Brian Olshansky
WSWin-Kuang Shen
Win-Kuang Shen
HCHugh Calkins
Hugh Calkins
KKKhalil Kanjwal
Khalil Kanjwal

24 June 2015 in EP Europace
Verified
Journal Article
Open access
PDF file
RKRose Anne Kenny
Rose Anne Kenny
MBMichele Brignole
Michele Brignole
GDGheorghe-Andrei Dan
Gheorghe-Andrei Dan
JDJean Claude Deharo
Jean Claude Deharo
JDJ. Gert van Dijk
J. Gert van Dijk
EFExternal Contributors To The Task Force
External Contributors To The Task Force
The European Society of Cardiology (ESC) has played an important role in advancing our understanding of the causes, optimal investigation, and management of syncope through publication of practice guidelines in 2001, 2004, and 2009.1–3 The 2009 ESC guidelines recommend the establishment of formal Syncope Units (SUs)—either virtual or physical site within a hospital or clinic facility—with access to syncope specialists and specialized equipment.3 In response, this position statement by the European Heart Rhythm Association (EHRA) endorsed by the Heart Rhythm Society (HRS) offers a pragmatic approach to the rationale and requirement for an SU, based on specialist consensus, existing practice and scientific evidence (see Appendix).

1 February 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
EREsteban W. Rivarola
Esteban W. Rivarola
DHDenise Hachul
Denise Hachul
TWTan Wu
Tan Wu
CPCristiano Pisani
Cristiano Pisani
CHCarina Hardy
Carina Hardy
MSMaurício Scanavacca
Maurício Scanavacca
Background—: Autonomic denervation is an alternative approach for patients with symptomatic bradycardia. No consensus exists on the critical targets and end points of the procedure. The aim of this study was to identify immediate end points and critical atrial regions responsible for vagal denervation. Methods and Results—: We enrolled 14 patients (50% men; age: 34.0±13.8 years) with cardioinhibitory syncope, advanced atrioventricular block or sinus arrest, and no structural heart disease. Anatomic mapping of ganglionated plexuses was performed, followed by radiofrequency ablation. Heart rate, sinus node recovery time, Wenckebach cycle length, and atrial-His (AH) interval were measured before and after every radiofrequency pulse. Wilcoxon signed-rank test was used for comparison. Significant shortening of the R-R interval ( P =0.0009), Wenckebach cycle length ( P =0.0009), and AH intervals ( P =0.0014) was observed after ablation. The heart rate elevation was 23.8±12.5%, and the Wenckebach cycle length and AH interval shortening was 18.1±11% and 24.6±19%, respectively. Atropine bolus injection (0.04 mg/kg) did not increase heart rate further. Targeting a single spot of the left side (64% of the patients) or right side (36%) of the interatrial septum was observed to be responsible for ≥80% of the final R-R and AH interval shortening during ablation. Conclusions—: Targeting specific sites of the interatrial septum is followed by an increase in heart rate and atrioventricular nodal conduction properties and might be critical for vagal attenuation. The R-R interval, Wenckebach cycle length, and AH interval shortening, associated with a negative response to atropine, could be considered immediate end points of the procedure.

3 May 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PVPedro Veronese
Pedro Veronese
DHDenise Hachul
Denise Hachul
MSMaurício Scanavacca
Maurício Scanavacca
LHLudhmila Abrahão Hajjar
Ludhmila Abrahão Hajjar
TWTan Chen Wu
Tan Chen Wu
FDFrancisco Carlos da Costa Darrieux
Francisco Carlos da Costa Darrieux
Acute and subacute cardiotoxicity are characterized by prolongation of the corrected QT interval (QTc) and other measures derived from the QTc interval, such as QTc dispersion (QTdc) and transmural dispersion of repolarization (DTpTe). Although anthracyclines prolong the QTc interval, it is unclear whether breast cancer patients who undergo the ACT chemotherapy regimen of anthracycline (doxorubicin: A), cyclophosphamide (C) and taxane (T) may present with QTc, QTdc and DTpTe prolongation. Twenty-three consecutive patients with breast cancer were followed prospectively during ACT chemotherapy and were analyzed according to their QT measurements. QTc, QTdc and DTpTe measurements were determined by a 12-lead electrocardiogram (EKG) prior to chemotherapy (baseline), immediately after the first phase of anthracycline and cyclophosphamide (AC) treatment, and immediately after T treatment. Serum troponin and B-type natriuretic peptide (BNP) levels were also measured. Compared to baseline values, the QTc interval was significantly prolonged after the AC phase (439.7 ± 33.2 ms vs. 472.5 ± 36.3 ms, p = 0.001) and after T treatment (439.7 ± 33.2 ms vs. 467.9 ± 42.6 ms, p < 0.001). Troponin levels were elevated after the AC phase (23.0 pg/mL [min-max: 6.0–85.0] vs. 6.0 pg/mL [min-max: 6.0–22.0], p < 0.001) and after T treatment (25.0 pg/mL [min-max: 6.0–80.0] vs. 6.0 pg/mL [min-max: 6.0–22.0], p < 0.001) compared to baseline values. In this prospective study of patients with non-metastatic breast cancer who underwent ACT chemotherapy, significant QTc prolongation and an elevation in serum troponin levels were observed.

21 April 2009 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
MSMaurício Scanavacca
Maurício Scanavacca
DHDenise Hachul
Denise Hachul
CPCristiano Pisani
Cristiano Pisani
ESEduardo Sosa
Eduardo Sosa

1 February 2015 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
MSMaurício Scanavacca
Maurício Scanavacca
EDUARDO BACK STERNICKEDUARDO BACK STERNICK
EDUARDO BACK STERNICK
CPCristiano Pisani
Cristiano Pisani
SLSissy Lara
Sissy Lara
CHCarina Hardy
Carina Hardy
ESEduardo A. Sosa
Eduardo A. Sosa
Background—: Epicardial mapping and ablation of accessory pathways through a subxiphoid approach can be an alternative when endocardial or epicardial transvenous mapping has failed. Methods and Results—: We reviewed acute and long-term follow-up of 21 patients (14 males) referred for percutaneous epicardial accessory pathway ablation. There was a median of 2 previous failed procedures. All patients were highly symptomatic, 8 had atrial fibrillation (3 with cardiac arrest) and 13 had frequent symptomatic episodes of atrioventricular reentrant tachycardia. Six patients (28.5%) had a successful epicardial ablation. Five patients (23.8%) underwent a successful repeated endocardial mapping, and ablation after epicardial mapping yielded no early activation site. Epicardial mapping was helpful in guiding endocardial ablation in 2 patients (9.5%), showing that the earliest activation was simultaneous at the epicardium and endocardium. Four patients (19%) underwent successful open-chest surgery after failing epicardial/endocardial ablation. Two patients (9.5%) remained controlled under antiarrhythmic drugs after unsuccessful endocardial/epicardial ablation. Two patients had a coronary sinus diverticulum and one a right atrium to right ventricle diverticulum. Three patients acquired postablation coronary sinus stenosis. There was no major complication related to pericardial access. Conclusions—: Percutaneous epicardial approach is an alternative when conventional endocardial or transvenous epicardial ablation fails in the elimination of the accessory pathway. A new attempt by endocardial approach was successful in a significant number of patients. Open-chest surgery may be required in symptomatic cases refractory to endocardial–epicardial approach.